CA2920272A1 - Compositions therapeutiques renfermant de la phenazine-3-one et des derives de phenothiazine-3-one et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux - Google Patents

Compositions therapeutiques renfermant de la phenazine-3-one et des derives de phenothiazine-3-one et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux Download PDF

Info

Publication number
CA2920272A1
CA2920272A1 CA2920272A CA2920272A CA2920272A1 CA 2920272 A1 CA2920272 A1 CA 2920272A1 CA 2920272 A CA2920272 A CA 2920272A CA 2920272 A CA2920272 A CA 2920272A CA 2920272 A1 CA2920272 A1 CA 2920272A1
Authority
CA
Canada
Prior art keywords
deficiency
syndrome
mitochondrial
myopathy
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2920272A
Other languages
English (en)
Inventor
D. Travis Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Biotherapeutics Corp
Original Assignee
Stealth Biotherapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Corp filed Critical Stealth Biotherapeutics Corp
Publication of CA2920272A1 publication Critical patent/CA2920272A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2920272A 2015-02-13 2016-02-09 Compositions therapeutiques renfermant de la phenazine-3-one et des derives de phenothiazine-3-one et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux Abandoned CA2920272A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562115955P 2015-02-13 2015-02-13
US62/115,955 2015-02-13

Publications (1)

Publication Number Publication Date
CA2920272A1 true CA2920272A1 (fr) 2016-08-13

Family

ID=56611663

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2920272A Abandoned CA2920272A1 (fr) 2015-02-13 2016-02-09 Compositions therapeutiques renfermant de la phenazine-3-one et des derives de phenothiazine-3-one et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux

Country Status (1)

Country Link
CA (1) CA2920272A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111556750A (zh) * 2017-11-07 2020-08-18 学校法人自治医科大学 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途
US11834697B2 (en) 2017-09-15 2023-12-05 Oxford University Innovation Limited Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11834697B2 (en) 2017-09-15 2023-12-05 Oxford University Innovation Limited Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
CN111556750A (zh) * 2017-11-07 2020-08-18 学校法人自治医科大学 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途
EP3708161A4 (fr) * 2017-11-07 2021-08-18 Jichi Medical University Agent visant à améliorer un dysfonctionnement mitochondrial, agent préventif ou thérapeutique pour des maladies ou des symptômes provoqués par un dysfonctionnement mitochondrial, et leurs applications
US11369615B2 (en) 2017-11-07 2022-06-28 Jichi Medical University Agent for improving mitochondrial dysfunction, preventative or therapeutic agent for diseases or symptoms caused by mitochondrial dysfunction, and applications therefor
CN111556750B (zh) * 2017-11-07 2023-05-26 学校法人自治医科大学 线粒体功能障碍的改善剂和由线粒体功能障碍引起的疾病或症状的预防或治疗药物及其用途

Similar Documents

Publication Publication Date Title
CA2984407A1 (fr) Compositions therapeutiques renfermant un triterpenoide et utilisations associees en vue de traiter et prevenir les maladies mitochondriales
Mills et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice
Andreani et al. Combination of coenzyme Q10 intake and moderate physical activity counteracts mitochondrial dysfunctions in a SAMP8 mouse model
JP6879980B2 (ja) ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
CA2917336A1 (fr) Compositions therapeutiques renfermant des derives de catecol et ses utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux
Choi et al. Oxidative stress‐mediated skeletal muscle degeneration: Molecules, mechanisms, and therapies
CA2973885A1 (fr) Compositions therapeutiques renfermant des composes de creatine ciblant les mitochondries et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux
Ma et al. BCAA–BCKA axis regulates WAT browning through acetylation of PRDM16
CA2881746A1 (fr) Compositions therapeutiques renfermant des peptides inhibiteurs de fission mitochondriale, des variants de ceux-ci, et methodes d'utilisation associees en vue de traiter et prevenir les maladies et troubles mitochondriaux
Xu et al. Epigenetic regulation of chondrocyte hypertrophy and apoptosis through Sirt1/P53/P21 pathway in surgery-induced osteoarthritis
Egorova et al. Molecular mechanisms and therapeutics for spinocerebellar ataxia type 2
US20210401776A1 (en) Method of treating refractory epilepsy syndromes using fenfluramine enantiomers
He et al. ALDH2 attenuates early-stage STZ-induced aged diabetic rats retinas damage via Sirt1/Nrf2 pathway
JP2019523217A (ja) ミトコンドリアミオパシーの予防および治療のための組成物および方法
CA2893245A1 (fr) Compositions therapeutiques renfermant du bpm 31510, des variantes et analogues de celui-ci et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux
CA2973891A1 (fr) Compositions therapeutiques renfermant des composes de creatine modifies et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux
Venugopal et al. Monogenic diseases in India
Dolci et al. Therapeutic induction of energy metabolism reduces neural tissue damage and increases microglia activation in severe spinal cord injury
JP2016540762A5 (fr)
Errasti-Murugarren et al. Heteromeric amino acid transporters in brain: from physiology to pathology
JP7053692B2 (ja) 神経変性障害の治療又は予防のための細胞内Ｎｉｘ介在性マイトファジーを増大させる剤及び方法並びにキット
Wang et al. Ursolic acid ameliorates amyloid β-induced pathological symptoms in Caenorhabditis elegans by activating the proteasome
WO2015017861A1 (fr) Méthodes et compositions pour la prévention et le traitement de l'ataxie de friedreich
CA2920272A1 (fr) Compositions therapeutiques renfermant de la phenazine-3-one et des derives de phenothiazine-3-one et leurs utilisations en vue de traiter et prevenir les maladies et troubles mitochondriaux
JP4607453B2 (ja) ミトコンドリア性疾患を処置するための組成物および方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190211

FZDE Discontinued

Effective date: 20190211